81
Pro
0
Against

People who took the drug ended up with a smaller waist compared to their hips — a sign their body fat shifted from the belly to less dangerous areas.

Scientific Claim

Tesamorelin (2 mg subcutaneous daily) causes a reduction in waist-hip ratio in HIV-infected adults on antiretroviral therapy with central fat accumulation over 6 months, indicating a favorable redistribution of body fat away from the abdomen.

Original Statement

Trunk fat (P < 0.001), waist circumference (P = 0.02), and waist-hip-ratio (P = 0.001) improved, with no change in limb or abdominal SC fat.

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

The RCT design with a statistically significant change in a validated anthropometric marker supports definitive causal language. The claim accurately reflects the reported data.

Evidence from Studies

Supporting (1)

81

This study found that a daily shot of tesamorelin helped HIV patients lose belly fat without losing fat from their arms or legs, making their waist smaller compared to their hips — exactly what the claim says.

Contradicting (0)

0
No contradicting evidence found